Safety, Tolerability, and Pharmacokinetics of Multiple-Dose RFUS-949 in Healthy Chinese Participants

Inclusion Criteria: * Signed informed consent form (ICF) prior to the study, fully understands the study content, procedures, and possible adverse reactions; willing to participate and able to complete the study according to the protocol requirements. * Male or female, aged 18 to 45 years (inclusive). * Body weight \>= 50.0 kg for males and \>= 45.0 kg for females, with Body Mass Index (BMI) between 19.0 and 28.0 kg/m\^2 (inclusive). * Female participants and their partners are willing to have no pregnancy plans and use effective contraception methods from 2 weeks prior to screening up to 6 months after the last dose; male participants and their partners are willing to have no pregnancy plans and use effective contraception methods from signing the ICF up to 6 months after the last dose. No sperm or egg donation plans during this period. Exclusion Criteria: * Known allergy to the active ingredient or excipients of the study drug, history of specific allergies (e.g., asthma, urticaria, eczema), or highly allergic constitution (e.g., allergic to two or more drugs/foods, highly sensitive to environmental substances). * History or presence of clinically significant diseases requiring exclusion as judged by the investigator, including but not limited to neurological/psychiatric, respiratory, cardiovascular, hematological/lymphatic, urinary, endocrine, immune system diseases, and metabolic abnormalities. * History of dysphagia or gastrointestinal diseases, especially those affec…